Century Therapeutics (IPSC) Stock News
$IPSC · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Century Therapeutics (IPSC) in the past 30 days. BORSA’s news read on IPSC is bullish at 62/100, based on 1 company event over the past 7 days.
The wire on $IPSC
newest first · updated · direct subject stories onlyCentury Therapeutics reports Q3 loss of $23.5M, cash runway into 2029, pipeline on track
Century Therapeutics (IPSC) reported a Q3 2026 net loss of $23.5M, improved from $34.4M a year ago. Cash and investments stood at $174.1M, funding operations into 1Q 2029. The company reiterated plans to submit an IND for its type 1 diabetes therapy CNTY-813 in 4Q 2026 and to initiate a clinical trial for CNTY-308 in 2026.
bullish 65 · impact 40The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card Century Therapeutics (IPSC) stock: common questions
What is the latest Century Therapeutics stock news?
The highest-impact IPSC story BORSA published in the past 30 days:
· Century Therapeutics reports Q3 loss of $23.5M, cash runway into 2029, pipeline on track